GlassScriptPhysician profile
David M Murdock
NPI 1508830316
$18,116.91
in general payments reported to CMS, 2019-2025
28 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $10K · 2021: $230 · 2022: $2,176 · 2023: $2,360 · 2024: $2,609 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,045 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,044.75 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $10,365.35 | 2020 | |
| Abbvie INC. | $1,285.13 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $822.61 | 2019-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Indivior INC. | $653.72 | 2022-2024 | Sublocade, Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $608.38 | 2022-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $551.69 | 2021-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $532.62 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $466.28 | 2023-2024 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $457.27 | 2021-2024 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $453.00 | 2019-2024 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $425.17 | 2019-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $280.33 | 2022 | |
| Vanda Pharmaceuticals INC. | $267.42 | 2022-2024 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $243.79 | 2022-2024 | Trintellix |
| Noven Therapeutics, LLC | $202.15 | 2022-2024 | Xelstrym, Secuado |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $96.17 | 2022-2024 | Azstarys |
| Lsi Solutions INC | $85.37 | 2022 | |
| Idorsia Pharmaceuticals US INC | $59.09 | 2022-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $53.32 | 2024 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $39.76 | 2024 | Cobenfy |
| Gilead Sciences, INC. | $39.69 | 2023 | Epclusa |
| Eisai INC. | $22.65 | 2022 | |
| Bausch Health US, LLC | $22.04 | 2022 | |
| Braeburn INC. | $19.43 | 2024 | Brixadi |
| Alfasigma USA, INC. | $18.97 | 2022 | |
| Sage Therapeutics, LLC | $17.82 | 2024 | |
| Ironshore Pharmaceuticals INC. | $15.26 | 2022 | |
| Merck Sharp & Dohme LLC | $12.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Murdock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.